Topic: Smpd3

Schizophrenia is a highly heterogeneous psychiatric disorder, which is elicited by multiple genetic and non-genetic factors. It remains insufficiently treatable with the current pharmaceutical approaches. In this study, we describe a new pathological mechanism and identify a new pharmacological treatment target with the use of a recently introduced ligand for it. An initial analysis of human gene polymorphisms and brain gene expression in schizophrenia patients identified an association of Smpd1 and Smpd3 genes coding for acid- (ASM) and neutral sphingomyelinase (NSM). In a rat model of amphet

Alcohol abuse and depression are severe comorbid psychiatric illnesses often accompanied by peripheral disorders, such as osteoporosis. Crucial members of biological membranes, ceramides, contribute to the pathogenesis of single disorders, while role of the ceramide system in their comorbidities remains unclear. We observed the specific contribution of an enzyme of the ceramide metabolism, neutral sphingomyelinase (NSM), in the comorbidity of alcohol use disorder, anxiety/depression, and osteoporosis. A genetic association analysis performed on 456,693 participants showed an association betwee